Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

Our writer isn't convinced by the answers that AI assistant ChatGPT rattled off when asked about solid FTSE 100 defensive ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

Pharma firm GSK has been accused of burying a report said to prove a link between its medication Zantac and cancer, a new ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Wall Street suffers its worst day since 2020 but the White House tells investors to "trust in President Trump".

Pharmaceutical stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts cautioned that the ...